Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/CMAR.S146173 http://scihub22266oqcxt.onion/10.2147/CMAR.S146173 C5677376!5677376!29138596     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cancer+Manag+Res 2017 ; 9 (ä): 565-72 Nephropedia Template TP {{tp|p=29138596|t=2017. Nifuratel, a novel STAT3 inhibitor with potent activity against human gastric cancer cells |pdf=|usr=}}{{29138596}} gab.com Text Nifuratel, a novel STAT3 inhibitor with potent activity against human gastric cancer cells JO: Cancer Manag Res http://www.kidney.de/pget.php?&tw=1&pmid=29138596 #FOAvip Activation of the signal transducer and activator of transcription 3 (STAT3) is observed in multiple cancer types, including gastric cancer, and represents a potential drug target for chemotherapy. Currently, clinically available small-molecule inhibitors targeting STAT3 are lacking. Here, we report that nifuratel, an antiprotozoal and antifungal drug, is a potent inhibitor of STAT3. We found that nifuratel significantly suppressed proliferation and induced apoptosis of gastric cancer cells. Studies of the mechanism of action of nifuratel indicated that it acts by inhibiting the constitutive and interleukin-6-induced STAT3 activation. Taken together, our findings demonstrate that nifuratel may be a novel, clinically accessible STAT3 inhibitor in gastric cancer cells. Twit Text FOAVip Nifuratel, a novel STAT3 inhibitor with potent activity against human gastric cancer cells ????Cancer Manag Res http://www.kidney.de/pget.php?&tw=1&pmid=29138596 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29138596 #FOAvip English Wikipedia <ref>{{Cite pmid|29138596}}</ref> Nifuratel, a novel STAT3 inhibitor with potent activity against human gastric cancer cells #MMPMID29138596 Zheng H; Hong H; Zhang L; Cai X; Hu M; Cai Y; Zhou B; Lin J; Zhao C; Hu W Cancer Manag Res 2017[]; 9 (ä): 565-72 PMID29138596show ga Activation of the signal transducer and activator of transcription 3 (STAT3) is observed in multiple cancer types, including gastric cancer, and represents a potential drug target for chemotherapy. Currently, clinically available small-molecule inhibitors targeting STAT3 are lacking. Here, we report that nifuratel, an antiprotozoal and antifungal drug, is a potent inhibitor of STAT3. We found that nifuratel significantly suppressed proliferation and induced apoptosis of gastric cancer cells. Studies of the mechanism of action of nifuratel indicated that it acts by inhibiting the constitutive and interleukin-6-induced STAT3 activation. Taken together, our findings demonstrate that nifuratel may be a novel, clinically accessible STAT3 inhibitor in gastric cancer cells. äNifuratel, a novel STAT3 inhibitor with potent activity against human (epmc).pdf DeepDyve Pubget Overpricing